BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Pfizer and its German partner BioNTech currently produce one of the most sought-after Covid-19 vaccines. Below are some of the recent updates relating to the shot.

Pfizer Covid-19 Vaccine Updates: Booster Shots, E.U. Supplies

Moderna

Money and pipelines are the two most important factors in picking the most likely to succeed.

The Biggest mRNA Winner: Pfizer, BioNTech, Moderna, or an Under-the-Radar Biotech?

AstraZeneca's pain is resulting in a big gain for Pfizer and BioNTech.

Pfizer and BioNTech Vaccine Sales Jump $1.4 Billion Thanks to AstraZeneca's Blunders

The European Commission exercises its option to purchase an additional 100 million doses of Pfizer (PFE)/ BioNTech's COVID-19 vaccine, Comirnaty, for EU member states.

Pfizer (PFE)/ BioNTech to Supply Extra Comirnaty Doses to EU

NEW YORK and MAINZ, GERMANY, April 19, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 vaccine, to the 27 European Union (EU) member states in 2021. This announcement is a result of the European Commission's (EC) decision to exercise its option to purchase an additional 100 million doses under its expanded Advanced Purchase Agreement signed on February 17, 202 1. This brings the total number of doses to be delivered to the EU to 600 million.

Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®

Studies are still under way to determine whether additional booster shots are needed to maintain immunity, but Pfizer's CEO calls it "a likely scenario."

Pfizer CEO: COVID-19 vaccine may require third dose within 12 months

Pfizer CEO Albert Bourla said earlier this month that people will likely require booster shots within 12 months of getting fully vaccinated — as early as December for some. "It is extremely important to suppress the pool of people that can be susceptible to the virus," Bourla told CNBC's Bertha Coombs on April 1.

People will likely need a booster shot of Pfizer's vaccine within 12 months, Pfizer's CEO said

Pfizer CEO Albert Bourla said people will “likely” need a third dose of a Covid-19 vaccine within 12 months of getting fully vaccinated.

Pfizer CEO says third Covid vaccine dose likely needed within 12 months

AstraZeneca

Johnson & Johnson

A comparison between COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX), Moderna's (MRNA), AstraZeneca (AZN) and J&J (JNJ) is inevitable.

Which Vaccine Maker Will Win the Fight Against COVID-19?

The European Union has reached an agreement to speed up delivery of 50 million more doses of the BioNTech-Pfizer COVID-19 vaccines to boost the continent's vaccination program. "Those 50 million doses were initially foreseen for delivery in the fourth quarter of 2021.

EU moves up delivery for 50 million BioNTech and Pfizer COVID-19 doses

Novavax

Bad news for J&J could be good news for these biotechs.

Why Novavax and BioNTech Stocks Are Jumping Today

Shares of Moderna Inc. shot up 8.6% in morning trading, BioNTech SE ran up 5.7% toward a 4-month high and Pfizer Inc. climbed 1.1% toward a 3-month high, after U.S. health regulators paused the use of Johnson & Johnson's COVID-19 vaccine "out of an abundance of caution" as a result of rare blood clotting cases. Meanwhile, J&J shares shed $2.98, or 1.8%, to shave about 20 points of the Dow Jones Industrial Average's price, as the Dow dropped 132 points, or 0.4%.

Moderna, BioNTech stocks surge after regulators halt use of J&J vaccine

Johnson & Johnson's (NYSE: JNJ) pain has proved to be gain for other vaccine companies, including BioNTech SE (NASDAQ: BNTX), Pfizer Inc. (NYSE: PFE), Moderna, Inc. (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX). What Happened: The Food and Drug Administration and the Centers for Disease Control and Prevention announced it's recommending pausing of the use of J&J's single-shot coronavirus vaccine, attributing the decision on incidents of severe, atypical blood clots.

Why Vaccine Stocks Pfizer, BioNTech, Moderna And Novavax Are Higher

It can already claim it contributed to both companies' COVID vaccines.

A Surprising Vaccine Rival May Upset the Dreams of Anyone Holding Moderna and Pfizer Stock

According to a real-world data study in Israel, the coronavirus variant discovered in South Africa may dodge the protection provided by Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine to some extent. It is also noted that the South African variant, B.1.351, made up about 1% of all the COVID-19 cases across all the people studied in the country, and the research has not been peer-reviewed.

South African Variant Able To Elude Pfizer/BioNTech' Vaccine Protection, Israeli Study Shows: Report

Regeneron Pharmaceuticals

Nearly everyone will get the Covid-19 vaccination, suggesting strong revenue for a handful of pharmaceutical companies. The post Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks appeared first on InvestorPlace.

Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks

BioNTech SE Sponsored ADR (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

BioNTech SE Sponsored ADR (BNTX) Moves 6.7% Higher: Will This Strength Last?

The coronavirus variant first discovered in South Africa is able to evade some of the protection of the Pfizer-BioNTech vaccine, according to an Israeli study.

Covid variant from South Africa was able to ‘break through' Pfizer vaccine in Israeli study

Coronavirus variants first found in South Africa and the UK are able to partially "breakthrough" the Pfizer/BioNTech vaccine, according to an Israeli study that studied real-world infection data. The study has not yet been peer-reviewed. The study, released on Saturday, compared the incidences of both variants between vaccinated and unvaccinated patients who had tested positive for the coronavirus. The study, conducted by Tel Aviv University and Israeli healthcare provider Clalit tracked almost 400 people, and counted both partially vaccinated (one dose) and fully vaccinated (two dose) patients.

Pfizer vaccine may be less effective against South African and UK coronavirus variants, according to Israeli study

If investors are expecting BNTX stock to continue generating double digit gains, they should be taking a careful look at its pipeline. The post What Can BioNTech Do for an Encore?

What Can BioNTech Do for an Encore?

Pharmaceutical giant Pfizer announced on Friday that it submitted a request for emergency use authorization to begin administering its COVID-19 vaccine to adolescents between the ages of 12 and 15 in the U.S.

Pfizer requests emergency use authorization to administer COVID-19 vaccine to adolescents

The request comes just days after Pfizer released clinical trial data demonstrating its vaccine was 100% effective and well tolerated by the younger age group.

Pfizer asks FDA to clear its COVID-19 vaccine for use in kids ages 12 to 15

Pfizer's shot could be the first coronavirus vaccine approved for 12- to 15-year-olds.

Pfizer Asks FDA To Approve Its Covid Vaccine For Younger Teenagers

The European Commission is reportedly seeking EU governments' approval to get into talks with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to purchase up to 1.8 billion doses of their COVID-19 vaccines to be delivered in 2022 and 2023, Reuters reported. Earlier today, German daily Die Welt reported that the Commission was to sign contracts shortly to buy up to 1.8 billion doses but did not say with which company.

European Union Looks To Buy 1.8B Pfizer-BioNTech COVID-19 Vaccine Doses From 2022: Reuters

Pfizer and BioNTech and requested that US regulatory agencies to make their COVID-19 vaccine available for adolescents aged 12 to 15. In a press release issued on Friday, the companies said they plan to make similar requests worldwide in coming days.

News for BioNTech SE Stock (BNTX)